Left ventricular diastolic function with epirubicin therapy: an echodoppler study.
Thirty patients undergoing epirubicin therapy for primary lung cancer were studied by echocardiography and Doppler echocardiography. 2 D ejection fraction (EF) and Doppler left ventricular filling parameters (peak E, peak A, E/A ratio) were calculated before and after the completion of therapy. No differences in the mean values of these parameters were observed. However, 6 out of 30 patients (20%) showed left ventricular filling abnormalities; in 2 of them a slight reduction of EF was also noted. These abnormalities seem to be dose related. A longer term prospective study will be required to evaluate whether these findings are irreversible and to establish the clinical implications of our observations.
Maione
S
S
I Clinica Medica, II Facoltà di Medicine, Università di Napoli, Italy.
Giunta
A
A
Itri
F
F
Losardo
L
L
Palma
M
M
Giacummo
A
A
De Blasio
F
F
De Matteis
L
L
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D003971:Diastole; D004452:Echocardiography; D015150:Echocardiography, Doppler; D015251:Epirubicin / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D013318:Stroke Volume / Q000187:drug effects*; D016277:Ventricular Function, Left / Q000187:drug effects*
D015251:Epirubicin